Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Cellectis Price Performance

NASDAQ CLLS opened at $1.76 on Tuesday. The stock has a market capitalization of $97.82 million, a price-to-earnings ratio of -1.28 and a beta of 3.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. Cellectis has a 1-year low of $1.75 and a 1-year high of $3.77. The business’s fifty day moving average price is $2.11 and its 200-day moving average price is $2.29.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. The firm had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. On average, equities analysts predict that Cellectis will post -0.54 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

A number of hedge funds have recently made changes to their positions in CLLS. XTX Topco Ltd bought a new position in Cellectis during the second quarter valued at $29,000. First Affirmative Financial Network purchased a new stake in Cellectis during the 3rd quarter valued at $45,000. Principal Financial Group Inc. boosted its stake in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC boosted its stake in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the period. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.